Core Insights - Lexeo Therapeutics announced preliminary data from the HEROIC-PKP2 Phase I/II clinical trial of LX2020, indicating that the treatment was generally well tolerated and led to significant improvements in PKP2 protein expression and arrhythmia burden in participants [2][3]. Group 1: Clinical Trial Results - The HEROIC-PKP2 trial involved ten participants, with three in the low-dose cohort and seven in the high-dose cohorts [4]. - LX2020 resulted in a mean increase in PKP2 protein expression of 93% in the low-dose cohort and 162% in the high-dose cohorts [8]. - Non-sustained ventricular tachycardia (NSVT) showed a 22% mean improvement in high-dose cohorts, while premature ventricular contractions (PVCs) had a 14% mean improvement [7][13]. - Four out of five participants in high-dose cohorts reported improvement on the Patient Global Impression of Change (PGIC) scale [13]. Group 2: Safety Profile - LX2020 was generally well tolerated, with no clinically significant complement activation reported [8]. - Elevations in liver function tests were observed in five participants at the high dose but resolved without complications [8]. - One serious adverse event of sustained ventricular tachycardia was noted, assessed as possibly treatment-related, but the participant was successfully treated [8]. Group 3: Next Steps and Future Outlook - The company plans to host a webcast to discuss these findings and future developments [9]. - Enrollment for the HEROIC-PKP2 trial was completed in Q4 2025, with 12-month data expected for all high-dose participants in Q4 2026 [13]. - Regulatory engagement is anticipated in 2026 as the company advances the development of LX2020 [13].
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy